This latest edition features articles on accelerating new therapies under the new FDA administration, cash-pay healthcare companies possibly facing kickback and fee-splitting risk under federal and state laws, building in-house legal teams for biotech, digital health, and medical devices companies, and life sciences venture financings for firm clients across 1H2025 and 2H2025.

The report also highlights the latest episodes of the NextGen VC Podcast focused on life sciences investing and the most recent additions to the Patents and Innovations Library for in-house IP counsel, as well as select life sciences client matters and upcoming events. 

Click here to read the June 2026 edition of The Life Sciences Report.